Johnson & Johnson’s pharma unit Janssen is driving awareness among Black Americans of the risks for peripheral artery disease (PAD)-related amputations in the “Save Legs. Change Lives.” campaign.
Johnson & Johnson is hoping Xarelto can win approval in peripheral and coronary artery disease patients after dropping positive data in August. Now, it has more results to back up its case—and help it ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results